Thursday, 24 September 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 6, 2025

Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®

View original at finance.yahoo.com
Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek® A post hoc analysis of REDEFINE 1 demonstrated a 10.9 mmHg reduction in systol…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Semaglutide 2.4 mg reduced systolic blood pressure by 8.8 mmHg over 68 weeks

    80% confidence

  • Overall discontinuation rates due to adverse events were low, with 6% for CagriSema versus 3.7% for placebo

    80% confidence

  • Obesity is a chronic relapsing progressive disease process

    80% confidence

  • The reduction in hsCRP with CagriSema (68.9%) was greater than with semaglutide 2.4 mg alone (55.4%) or placebo (16.0%)

    80% confidence

  • Fewer people on CagriSema were at intermediate-to-high risk of developing atherosclerotic cardiovascular disease within the next 10 years

    80% confidence

  • The hsCRP reduction with CagriSema was only partially explained by weight loss, suggesting that the inflammatory effects are not fully weight loss dependent

    80% confidence

  • Placebo reduced systolic blood pressure by 2.1 mmHg over 68 weeks

    80% confidence

  • CagriSema (2.4 mg/2.4 mg) demonstrated a 10.9 mmHg reduction in systolic blood pressure over 68 weeks

    80% confidence

  • The CagriSema data are very encouraging regarding the effects on well-known CV risk factors like high blood pressure

    80% confidence

  • 40% of people on blood pressure medications were able to reduce or stop their medication with CagriSema treatment

    80% confidence

  • People living with obesity have treatment goals that often include both losing weight and improving overall health

    80% confidence

  • Adverse events in REDEFINE 1 were mainly gastrointestinal (79.6% in the CagriSema group versus 39.9% with placebo) and were mostly transient and mild-to-moderate in severity

    80% confidence

  • CagriSema treatment demonstrated a nearly 70% reduction in hsCRP, a key inflammatory marker associated with increased cardiovascular risk

    80% confidence

Data points we hold from this source

Novo Nordisk · markets served170 countries
Novo Nordisk · us employee count10000 employees
Novo Nordisk · employee count78500 employees
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Go Mainstream, But Trustworthy Data Access Lags Adoption
A wave of enterprise AI agent activity — fresh funding (Latitude's $35M Series A), a run of CB Insights CEO interviews spotlighting fintech- and healthcare-focused agent startups (Covecta, Penguin AI, Maisa AI), and major platform partnerships (Microsoft-Mistral, Manulife-Microsoft AI governance, Siemens-NVIDIA agentic EDA, Box's agent security controls) — signals agentic AI moving from pilot to production across financial and enterprise workflows. Yet Google Cloud's own research shows adoption is outrunning data readiness (companies average AI access to only 45% of their data, with 'data laggards' capped near 30%), while insider selling at incumbent C3.ai hints at mixed investor conviction even as the broader ecosystem accelerates.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,983
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,983 facts checked against source5,305 source documents archived
Query this data → isubstrate.com
Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek® — Source | Via News | ViaNews EU